FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,872 letters match. Newest first.

  1. HealBerry

    FDA warned HealBerry that claiming compounded semaglutide has the 'same active ingredient as Ozempic and Wegovy' misbrands its drugs.

    Medium
  2. Reset IV, LLC dba Reset IV

    FDA warned Reset IV that its website misbrands compounded semaglutide and tirzepatide by claiming they are the same as FDA-approved drugs.

    Medium
  3. Yangzhou Yulou Paper Products Co., Ltd.

    FDA cited Yangzhou Yulou Paper Products for manufacturing violations after records showed its OTC sterile drugs lacked sterility assurance and testing.

    High risk
  4. inspire.clinic

    FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.

    Low
  5. Bioverse, Inc. dba Bioverse

    FDA warned Bioverse that its website made false or misleading claims for compounded semaglutide and tirzepatide drugs.

    Low
  6. SimpleRx

    FDA warned SimpleRx that its website falsely implied compounded semaglutide and tirzepatide were Ozempic or Zepbound.

    High risk
  7. Elevate Your Wellness LLC, dba Elevated

    FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.

    Low
  8. Cosmo Medical Spa dba Cosmo Med Spa

    FDA warned Cosmo Med Spa over its website selling compounded semaglutide with claims implying it is FDA-approved Ozempic.

    Medium
  9. eDrugstore

    FDA warns eDrugstore over claims that compounded tirzepatide is FDA-approved, making drugs misbranded (falsely promoted).

    High risk
  10. Nuvo Life Health Inc. dba Nuvo Life Health

    FDA warned Nuvo Life Health that its website sold compounded semaglutide and tirzepatide with misleading claims comparing them to FDA-approved drugs.

    Medium
  11. SemaBio

    FDA warned SemaBio that its website sold compounded semaglutide and called it 'generic semaglutide,' a false or misleading claim.

    Low
  12. directmeds.com, Inc. dba DirectMeds

    FDA warned DirectMeds that its website sold compounded semaglutide and tirzepatide with false or misleading claims implying they match FDA-approved drugs.

    High risk
  13. Hims & Hers Health, Inc. dba Hims

    FDA warns Hims that compounded semaglutide website claims are false or misleading and misbrand the drugs.

    High risk
  14. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  15. Mane & Steel, LLC. dba Mane & Steel

    FDA warns Mane & Steel over false 'clinically proven' claims for compounded semaglutide.

    Low
  16. Lumimeds

    FDA warns Lumimeds over website claims implying its compounded semaglutide and tirzepatide are FDA-approved.

    High risk
  17. GLP-1 Solution

    GLP-1 Solution sells unapproved compounded retatrutide online and misleadingly compares semaglutide and tirzepatide to FDA-approved brand drugs.

    High risk
  18. ASN-LABS

    ASN-LABS marketed unapproved compounded retatrutide and misleading semaglutide claims online, FDA says.

    High risk
  19. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  20. Canada Med Stop

    Canada Med Stop marketed compounded semaglutide online as FDA-approved and generic, making the drugs misbranded.

    Medium
  21. Healthy Male

    FDA warns Healthy Male that its website sells compounded tirzepatide with false or misleading 'clinically proven' weight-loss claims.

    Low
  22. Invigorate Med Spa

    Invigorate Med Spa's website claimed compounded semaglutide and tirzepatide were Wegovy and Mounjaro, making them misbranded.

    Low
  23. EA WORKS Limited Liability Company dba Trust Labs

    FDA warned Trust Labs it sold unapproved compounded retatrutide and made false FDA-approval claims for semaglutide and tirzepatide online.

    High risk
  24. Fancy Meds, LLC dba Fancy Meds

    FDA warns Fancy Meds that its compounded semaglutide and tirzepatide website claims are false or misleading.

    Low
  25. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  26. Elite Health Center

    FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.

    Low
  27. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  28. CSL Behring

    FDA says CSL Behring's HIZENTRA TV ad overstates protection and plays down risks, misbranding the immune globulin biologic.

    Medium
  29. Eli Lilly and Company

    FDA says Eli Lilly’s Oprah-linked video for Zepbound and Mounjaro misled on serious risks.

    High risk
  30. Novo Nordisk Inc.

    FDA says Novo Nordisk’s Oprah Winfrey video makes Wegovy, Ozempic and Victoza look safer than their labels allow.

    High risk
  31. Eli Lilly and Company

    FDA says Eli Lilly's Zepbound online video omitted risk and limitations information and was not submitted to FDA.

    High risk
  32. Eli Lilly and Company

    FDA says Eli Lilly's sponsored Zepbound video omitted risk and use information, misbranding the drug.

    Low
  33. Somerset Therapeutics Private Limited

    FDA cited Somerset Therapeutics' India plant for CGMP failures tied to a contaminated media fill and aseptic processing risks.

    High risk
  34. SeniorLife Technologies, Inc.

    FDA warns SeniorLife Technologies that its SeniorLife.AI app is unapproved and misbranded, with quality-system and reporting failures.

    High risk
  35. DingMoo LLC DBA Dingman’s Dairy

    DingMoo LLC DBA Dingman’s Dairy lacked Foreign Supplier Verification Program records for imported frozen desserts and Pistachio Tartufo tied to a Salmonella outbreak.

    High risk
  36. Mericon Industries, Inc.

    Mericon Industries sold Florical and Meribin supplements with unapproved drug claims for osteoporosis and serious manufacturing and labeling failures.

    High risk
  37. Shirish M. Gadgeel, M.D.

    Detroit clinical investigator Dr. Shirish Gadgeel enrolled ineligible subjects and missed required consent for genetic testing in drug trials.

    High risk
  38. Hikal Limited

    FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.

    High risk
  39. Jalisco Fresh Produce, Inc.

    Jalisco Fresh Produce lacks required foreign supplier checks for imported jalapeno peppers and white onions, FDA says.

    Medium
  40. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  41. Green Vitality dba Gr33n

    FDA warned Green Vitality dba Gr33n that its Jimerito Honey Eye Drops are an unapproved new drug sold with disease-treatment claims.

    High risk
  42. Homeopathic Educational Services dba Homeopathic Family Medicine

    FDA says Homeopathic Family Medicine sells unapproved Cineraria Maritima Eye Drops for cataracts online.

    High risk
  43. Supply Center USA

    Supply Center USA offered unapproved Similasan and Boiron eye drug products for sale online.

    High risk
  44. Wisconsin Pharmacal Company, LLC

    FDA warns Wisconsin Pharmacal over OTC drug manufacturing violations, including released rejected product and S. aureus contamination.

    High risk
  45. Chromatography Institute of America dba Compounder’s International Analytical Laboratory

    FDA warned Chromatography Institute of America, a Colorado contract drug testing lab, that sterility testing and quality controls violated current good manufacturing practice.

    High risk
  46. Synergy Animal Products, Inc.

    Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

    High risk
  47. Miach Orthopaedics

    FDA warns Miach Orthopaedics over quality-system failures in manufacturing its BEAR ACL Implant, including sterility monitoring and nonconforming product controls.

    High risk
  48. Innate Healthcare Institute

    FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.

    High risk
  49. Eurobread Inc. dba First Harvest

    FDA found Eurobread/First Harvest lacked required foreign supplier verification for imported Mini Patisseries tied to a Salmonella outbreak.

    High risk
  50. Uscom Kft

    Uscom Kft marketed SpiroSonic AIR spirometer in the U.S. without FDA clearance and had multiple quality system failures at its Budapest plant.

    High risk